DelveInsight’s, “Esophageal Cancer Pipeline Insight, 2023” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Esophageal Cancer pipeline landscape. It covers the Esophageal Cancer pipeline drug profiles, including Esophageal Cancer clinical trial and nonclinical stage products. It also covers the Esophageal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Esophageal Cancer pipeline products in this space.
In the Esophageal Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Esophageal Cancer clinical trial studies, Esophageal Cancer NDA approvals (if any), and product development activities comprising the technology, Esophageal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Esophageal Cancer Pipeline Report
To explore more information on the latest breakthroughs in the Esophageal Cancer treatment landscape of the report, click here @ Esophageal Cancer Pipeline Outlook
Recent Developmental Activities in the Esophageal Cancer Treatment Landscape
Esophageal Cancer Overview
Esophageal cancer develops in the esophagus, which is the tube that connects throat to the stomach. Tumors arise in the mucosa, which is the inner lining of the esophagus. There are two types of esophageal cancer, each with different risk factors: Adenocarcinoma -Cancers that start in gland cells at the bottom of the esophagus are called adenocarcinomas. This type of cancer is the most common esophageal cancer. It usually occurs closer to the stomach. Chronic acid reflux, gastroesophageal reflux disease (GERD), Barrett’s esophagus and chronic heartburn can increase the risk of developing adenocarcinoma esophageal cancer.
Request a sample and discover the recent advances in Esophageal Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Esophageal Cancer Treatment Landscape
Esophageal Cancer Emerging Drugs Profile
AN-0025: Adlai Nortye
AN0025 is a clinical stage, potential first-in-class EP4 antagonist designed to modulate tumor microenvironment. It blocks the PGE2-EP4 signaling pathway to inhibit PGE2-mediated immunosuppression in the tumor microenvironment. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Esophageal Cancer.
Tucatinib: Seagen
Tucatinib (TUKYSA®) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein, a protein that contributes to cancer cell growth.HER2 is overexpressed in multiple cancers, including breast, colorectal, and gastric cancers. In preclinical in vitro studies, TUKYSA inhibited phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell growth (proliferation), and showed anti-tumor activity in HER2-expressing tumor cells. In preclinical and clinical studies, TUKYSA inhibited the growth of HER2-expressing tumors. The combination of TUKYSA and the anti-HER2 antibody trastuzumab has also been shown to increase anti-tumor activity in vitro and in vivo compared to either medicine alone. Currently, the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Esophageal Cancer.
APX 005M: Apexigen
APX005M is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. APX005M targets CD40, a co-stimulatory receptor that is essential for activating both innate and adaptive immune systems. Binding of APX005M to CD40 on antigen presenting cells (i.e., dendritic cells, monocytes and B-cells) initiates a multi-faceted immune response bringing multiple components of the immune system (e.g., T cells, macrophages) to work in concert against cancer. APX005M is currently in Phase 2 clinical development for the treatment of cancers such as pancreatic cancer, esophageal and gastroesophageal junction cancers, melanoma, non-small cell lung cancer, rectal cancer and sarcoma in various combinations with immunotherapy, chemotherapy, radiation therapy or a cancer vaccine.
Esophageal Cancer Therapeutics Assessment
There is approx. 80+ key companies which are developing the therapies for Esophageal Cancer. The companies which have their Esophageal Cancer drug candidates in the most advanced stage, i.e. phase II/III include, Seagen.
For further information, refer to the detailed Esophageal Cancer Unmet Needs, Esophageal Cancer Market Drivers, and Esophageal Cancer Market Barriers, click here @ Esophageal Cancer Ongoing Clinical Trial Analysis
Esophageal Cancer Phases
Scope of the Esophageal Cancer Pipeline Report
Dive deep into rich insights for drugs for Esophageal Cancer Market Drivers and Esophageal Cancer Market Barriers, click here @ Esophageal Cancer Unmet Needs and Analyst Views
Table of Content
Key Questions
Current Treatment Scenario and Emerging Therapies:
Got Queries? Find out the related information of Esophageal Cancer mergers and acquisitions, Esophageal Cancer licensing activities, Esophageal Cancer emerging drugs, and Esophageal Cancer recent trends @ Esophageal Cancer Market Drivers and Barriers
About Us
DelveInsight’s is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021